PMS777, a New Cholinesterase Inhibitor with Anti-Platelet Activated Factor Activity, Regulates Amyloid Precursor Protein Processing In?Vitro

详细信息    查看全文

• 作者：Hong-Qi Yang ; Zhi-Kun Sun ; Yan-Xin Zhao ; Jing Pan ; Mao-Wen Ba ; Guo-Qiang Lu ; Jian-Qing Ding ; Hong-Zhuan Chen and Sheng-Di Chen
• 关键词：PMS777 ; Alzheimer’ ; s disease ; Amyloid precursor protein ; Cholinesterase inhibitor ; sAPPα ; ; Beta ; amyloid
• 刊名：Neurochemical Research
• 出版年：2009
• 出版时间：March, 2009
• 年：2009
• 卷：34
• 期：3
• 页码：528-535
• 全文大小：261.1 KB

文摘

Alzheimer’s disease (AD) is a neurodegenerative disorder characterized clinically by progressive impairment of memory and cognition. Previous data have shown that beta-amyloid (Aβ) cascade plays a central role in AD pathophysiology and thus drugs regulate amyloid precursor protein (APP) metabolism may have therapeutic potential. Here the effects of PMS777, a new cholinesterase inhibitor with anti-platelet activated factor activity, on APP processing were investigated. Using SH-SY5YAPP695 cells, it showed that PMS777 treatment caused significant decreased secretion of sAPPα into the conditioned media without affecting cellular holoAPP synthesis. When PC12 cells were incubated with PMS777, the same effect was observed. The data also indicated that 10 μM PMS777 incubation decreased the release of Aβ42 into the cell media as compared with vehicle group in SH-SY5YAPP695 cells. Pretreatment of cells with M-receptor scopolamine antagonized the decreased secretion of sAPPα induced by PMS777, but N-receptor α-bungarotoxin pretreatment did not have such an effect. These results indicated that PMS777 could modulate APP processing in vitro and that decreasing Aβ generation might demonstrate its therapeutic potential in AD.